Certara, Inc. ( (CERT) ) has released its Q4 earnings. Here is a breakdown of the information Certara, Inc. presented to its investors.
Certara, Inc. is a global leader in model-informed drug development, providing biosimulation software and services to biopharmaceutical companies, academic institutions, and regulatory agencies worldwide.
In its latest earnings report, Certara, Inc. announced a strong financial performance for the fourth quarter and full year 2024, with significant revenue growth and a return to profitability. The company also issued its financial guidance for 2025, indicating continued confidence in its strategic direction.
Certara reported a 14% increase in total revenue for the fourth quarter of 2024, reaching $100.4 million, driven by a 26% growth in software revenue and a 7% increase in services revenue. The company achieved a net income of $6.6 million compared to a net loss in the same period the previous year, and adjusted EBITDA rose by 13% to $33.5 million. The acquisition of Chemaxon contributed positively to these results, enhancing Certara’s biosimulation offerings.
The company’s bookings also saw substantial growth, with total bookings rising by 22% to $144.5 million. Software bookings increased by 38%, reflecting strong demand for Certara’s biosimulation software, while services bookings grew by 12%. The company plans to continue investing in software and AI to strengthen its biosimulation capabilities and capitalize on the growing interest in this technology across the biopharmaceutical industry.
Looking ahead, Certara’s management expects revenue for 2025 to be in the range of $415 million to $425 million, with adjusted EBITDA margins remaining in the low thirties. The company remains optimistic about its growth prospects and the potential returns from its strategic investments in biosimulation technology.